Living Cell Therapies Redefine Blood Cancer Care as Market Bets Shift
A new wave of cell-based and bispecific therapies is reshaping treatment for blood cancers, with recent approvals underscoring how quickly the field is moving from experimental science to standard care. The shift is clinically significant and commercially important, because it is changing survival expectations, treatment sequencing and the competitive landscape for drugmakers and investors.
